- Organized by the prestigious Galien Foundation and Business
France, the Prix Galien Medstartup rewards the best Franco-American
collaborations in the pharmaceutical sector.
- ACTICOR BIOTECH received this award for its collaboration
with Pr James Grotta at the Memorial Hermann Hospital, TX.
Acticor Biotech, a clinical stage biotechnology company working
on treatment for the acute phase of thrombotic diseases, has been
awarded the prix Galien Medstartup Award in the category “BEST
COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY” for
its collaboration with Pr James Grotta at the Memorial Hermann
Hospital, TX.
This collaboration aims to prepare an international clinical
trial ACTISAVE to evaluate the efficacy of glenzocimab in
patients suffering from acute ischemic stroke. ACTISAVE
(NCT05070260) will be an adaptive phase 2/3, multinational,
randomized, double-blind, multicenter, placebo-controlled, parallel
group, single dose, efficacy and safety study of glenzocimab used
as an add-on to standard of care therapy for acute ischemic
stroke.
“This joint recognition marks the milestones we have reached in
our work on glenzocimab to treat the acute phase of ischemic
stroke, and it highlights the importance of close collaboration
between a sponsor and clinical expert,” Commented Gilles
Avenard, CEO of Acticor Biotech.
“The current medical need in the treatment of ischemic stroke
requires collaborations with all parties to change the way we can
treat patients. At the Memorial Hermann Hospital, we are looking to
improve the time to needle of patients by developing the use of
Mobile Stroke Unit, but also are hopeful of the new options that
glenzocimab could bring in the treatment of acute phase of ischemic
stroke,” reacted James Grotta, professor of neurology and
director of Stroke Research, Clinical Institute for Research and
Innovation, Memorial Hermann - Texas Medical Center and the
Director of the Mobile Stroke Unit Consortium.
This eighth edition of the Galien Medstartup Awards was chaired
by Bernard Poussot, Director of Roche Holding and former Chairman
& CEO of Wyeth. This year again, the event featured a
remarkable world-renowned panel, rewarding the most innovative
projects in the healthcare industry.
About glenzocimab (ACT017), the Therapeutic Candidate
Acticor Biotech is developing glenzocimab (ACT017), a humanized
monoclonal antibody fragment (Fab). This therapeutic candidate is
directed against a novel target of major interest, platelet
glycoprotein VI (GPVI), and inhibits its action. Evidence of the
antithrombotic efficacy of glenzocimab and the safety of its
inhibition of GPVI has been established both ex vivo and in vivo.
This target is involved in growth of the thrombus but not in
physiological hemostasis, which thus limits the bleeding risk
associated with its inhibition.
https://acticor-biotech.com/technology/
About glenzocimab and Stroke
Glenzocimab is being currently assessed as an add-on to standard
of care therapy for ischemic stroke. Acticor Biotech has recently
announced the completion of patient enrolment in ACTIMIS
(NCT03803007), a multinational, multicenter, randomized,
double-blind, placebo-controlled, single-parallel, escalating dose
phase 1b/2a safety and efficacy study of glenzocimab. Acticor
recently announced the recruitment of the first patient in France
in ACTISAVE (NCT05070260). ACTISAVE is an adaptive phase 2/3,
multinational, randomized, double-blind, multicenter,
placebo-controlled, parallel group, single dose, efficacy and
safety study of glenzocimab used as an add-on to standard of care
therapy for acute ischemic stroke.
About Acticor Biotech
Acticor Biotech is a clinical stage biotechnology company, a
spin-off of INSERM (the French National Institute of Health and
Medical Research), dedicated to developing an innovative treatment
for cardiovascular emergencies, including ischemic stroke. Acticor
Biotech has been built on the expertise and research undertaken by
its co-founders: Dr. Martine Jandrot-Perrus at INSERM Paris and
Prof. Philippe Billiald at Paris-Sud University and Dr Gilles
Avenard. Acticor Biotech is a partner in the BOOSTER consortium,
dedicated to the management of, and novel treatments for,
cerebrovascular accidents in emergency situations.
Acticor Biotech is supported by a panel of European and
International investors: Karista, Go Capital, Newton Biocapital,
CMS Ventures, Mirae Asset Capital, Anaxago, Primer Capital,
Mediolanum farmaceutici & Armesa Foundation.
For more information, go to: https://acticor-biotech.com/
Disclaimer
This press release does not constitute or form a part of any
offer or solicitation to purchase or subscribe for securities in
the United States or any other jurisdiction (other than France).
Securities may not be offered or sold in the United States unless
they have been registered under the U.S. Securities Act of 1933, as
amended (the “U.S. Securities Act”), or are exempt from
registration. The shares of Acticor Biotech have not been and will
not be registered under the U.S. Securities Act and Acticor Biotech
does not intend to make a public offer of its shares in the United
States.
This information does not contain a solicitation for money,
securities or other consideration and, if sent in response to the
information contained herein, will not be accepted. This
announcement contains statements that are "forward-looking
statements" or could be considered as such. These forward-looking
statements can be identified by the use of forward-looking
terminology, including the words ‘believe’, ‘estimate’,
‘anticipate’, ‘expect’, ‘intend’, ‘may’, ‘will’, ‘plan’,
‘continue’, ‘ongoing’, ‘possible’, ‘predict’, ‘plans’, ‘target’,
‘seek’, ‘would’ or ‘should’, and contain statements made by the
Company regarding the intended results of its strategy. By their
nature, forward-looking statements involve risks and uncertainties
and readers are warned that none of these forward-looking
statements offers any guarantee of future performance. The
Company’s actual results may differ materially from those predicted
by the forward-looking statements. The Company makes no undertaking
whatsoever to publish updates or adjustments to these
forward-looking statements, unless required to do so by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211030005005/en/
ACTICOR BIOTECH Gilles AVENARD Directeur Général
gilles.avenard@acticor-biotech.com
NewCap Mathilde BOHIN / Olivier BRICAUD Relations
Investisseurs acticor@newcap.eu T. : 01 44 71 94 95
NewCap Annie-Florence LOYER Relations médias
afloyer@newcap.fr T. : 0 1 44 71 00 12
Acticor Biotech (EU:ALACT)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Acticor Biotech (EU:ALACT)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024